Zhitong Finance App News, Tibet Pharmaceutical (600211.SH) issued an announcement. Recently, ACCUREDIT THERAPEUTICS US LIMITED, a subsidiary of the company, received a notice from the US Food and Drug Administration (“FDA”) to agree to conduct clinical trials with Art002g1 injection.

Art002g1 injection indications: Adult heterozygous familial hypercholesterolemia (hEFH), and hypercholesterolemia in adults with high/very high risk atherosclerotic cardiovascular disease (ASCVD).

Art002G1 injection is an in vivo gene-editing drug targeting pCSK9 (proproteinase subtillisin 9). Art002G1 further optimizes components such as mRNA and gRNA on the basis of Art002. Currently, products with mechanisms of action such as monoclonal antibodies and siRNA (small interfering RNA) targeting PCSK9 have been approved for marketing, and no related products have been approved for marketing in vivo gene editing. As of the date of this announcement, the total R&D investment for this drug was RMB 66.0316 million (unaudited).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.